Becton, Dickinson and Company (NYSE:BDX) Position Trimmed by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 0.5% in the 1st quarter, HoldingsChannel.com reports. The fund owned 143,994 shares of the medical instruments supplier’s stock after selling 779 shares during the quarter. Becton, Dickinson and comprises approximately 2.8% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings, making the stock its 6th largest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Becton, Dickinson and were worth $38,779,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDX. Webster Bank N. A. lifted its stake in shares of Becton, Dickinson and by 3.9% in the 1st quarter. Webster Bank N. A. now owns 11,405 shares of the medical instruments supplier’s stock valued at $3,034,000 after purchasing an additional 433 shares during the period. Carret Asset Management LLC lifted its stake in shares of Becton, Dickinson and by 0.6% in the 1st quarter. Carret Asset Management LLC now owns 11,131 shares of the medical instruments supplier’s stock valued at $2,961,000 after purchasing an additional 71 shares during the period. CAPROCK Group Inc. lifted its stake in shares of Becton, Dickinson and by 7.8% in the 1st quarter. CAPROCK Group Inc. now owns 7,304 shares of the medical instruments supplier’s stock valued at $1,943,000 after purchasing an additional 531 shares during the period. First American Trust FSB acquired a new position in shares of Becton, Dickinson and in the 1st quarter valued at $209,000. Finally, Icapital Wealth LLC acquired a new position in shares of Becton, Dickinson and in the 1st quarter valued at $31,000. Institutional investors and hedge funds own 86.58% of the company’s stock.

Several equities analysts recently issued reports on the stock. Piper Sandler decreased their target price on shares of Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. StockNews.com cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, June 14th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research report on Monday, April 11th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Friday, April 1st. Finally, Bank of America started coverage on shares of Becton, Dickinson and in a research report on Tuesday, March 1st. They set a “neutral” rating for the company. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and presently has a consensus rating of “Hold” and an average target price of $280.83.

In related news, VP Thomas J. Spoerel sold 443 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $260.00, for a total value of $115,180.00. Following the sale, the vice president now owns 1,058 shares of the company’s stock, valued at $275,080. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David Hickey sold 475 shares of the firm’s stock in a transaction that occurred on Friday, May 6th. The shares were sold at an average price of $256.00, for a total transaction of $121,600.00. Following the completion of the sale, the executive vice president now directly owns 3,806 shares in the company, valued at approximately $974,336. The disclosure for this sale can be found here. 0.50% of the stock is currently owned by corporate insiders.

Becton, Dickinson and stock opened at $237.27 on Thursday. Becton, Dickinson and Company has a 52-week low of $231.46 and a 52-week high of $280.62. The firm has a market capitalization of $67.64 billion, a price-to-earnings ratio of 37.42, a PEG ratio of 3.20 and a beta of 0.64. The company has a fifty day simple moving average of $252.17 and a 200-day simple moving average of $258.20. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.20. The firm had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. Becton, Dickinson and’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.19 earnings per share. On average, research analysts anticipate that Becton, Dickinson and Company will post 11.2 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.47%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and’s dividend payout ratio (DPR) is presently 54.89%.

Becton, Dickinson and Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.